Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NMTC 
Neuroone Medical Technologies Corp (NMTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NMTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.23
1 Year Target Price $2.23
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.8% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.16M USD | Price to earnings Ratio - | 1Y Target Price 2.23 |
Price to earnings Ratio - | 1Y Target Price 2.23 | ||
Volume (30-day avg) 1 | Beta 0.65 | 52 Weeks Range 0.40 - 1.39 | Updated Date 10/17/2025 |
52 Weeks Range 0.40 - 1.39 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -80.5% | Operating Margin (TTM) -111.24% |
Management Effectiveness
Return on Assets (TTM) -45.07% | Return on Equity (TTM) -95.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37255601 | Price to Sales(TTM) 6.51 |
Enterprise Value 37255601 | Price to Sales(TTM) 6.51 | ||
Enterprise Value to Revenue 5.62 | Enterprise Value to EBITDA -2.1 | Shares Outstanding 49999519 | Shares Floating 43616580 |
Shares Outstanding 49999519 | Shares Floating 43616580 | ||
Percent Insiders 11.71 | Percent Institutions 33.7 |
Upturn AI SWOT
Neuroone Medical Technologies Corp
Company Overview
History and Background
NeuroOne Medical Technologies Corporation is a development-stage company focused on neural interface technology. Founded relatively recently, its primary focus is on developing and commercializing microelectrode technology for minimally invasive surgical applications.
Core Business Areas
- Thin Film Electrode Technology: Development and manufacturing of thin film electrode arrays for neural recording and stimulation.
- evo sEEG Electrode: Development and planned commercialization of the evo sEEG electrode for minimally invasive surgical applications.
Leadership and Structure
Information on current leadership and organizational structure is limited without live data. Check current financial reporting and press releases for up to date management structure.
Top Products and Market Share
Key Offerings
- evo sEEG Electrode: Minimally invasive electrode for seizure monitoring. Market share is currently negligible as the company is in the development and early commercialization phase. The competitors would be other established manufactures of sEEG electrodes. Potential competitors include Medtronic (MDT) and Integra LifeSciences (IART).
- Thin Film Electrode Technology: Technology used in potential future applications, including chronic pain management and spinal cord stimulation. Market share is currently negligible as the company is in the development and early commercialization phase. Competitors include Medtronic (MDT) and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The neuromodulation and neurodiagnostic market is growing, driven by advancements in technology and increasing prevalence of neurological disorders.
Positioning
NeuroOne is positioned as an innovator in minimally invasive neural interface technology. Their advantage lies in the design and potential capabilities of their thin film electrodes.
Total Addressable Market (TAM)
The total addressable market is estimated to be billions of dollars. NeuroOne is targeting specific segments within this market, such as epilepsy monitoring and chronic pain management. Their position is currently emerging.
Upturn SWOT Analysis
Strengths
- Innovative thin film electrode technology
- Potential for minimally invasive surgical applications
- Focus on unmet needs in epilepsy monitoring and pain management
Weaknesses
- Limited commercialization experience
- Dependence on regulatory approvals
- Limited financial resources compared to larger competitors
- Currently not profitable
Opportunities
- Partnerships with established medical device companies
- Expansion into new therapeutic areas
- Increasing demand for minimally invasive procedures
- Positive clinical trial results
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Technological obsolescence
- Potential for product liability claims
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Boston Scientific (BSX)
- Integra LifeSciences (IART)
Competitive Landscape
NeuroOne faces significant competition from established players. Its competitive advantage lies in its innovative technology and minimally invasive approach, but it needs to overcome financial and commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth as it is still in development stage.
Future Projections: Future growth depends on successful commercialization of products and market adoption. Analyst estimates should be reviewed for projections.
Recent Initiatives: Recent initiatives include product development milestones and strategic partnerships, if any. Check the latest press releases for these.
Summary
NeuroOne Medical Technologies is an emerging company with promising thin-film electrode technology but faces significant challenges related to commercialization, competition, and regulatory hurdles. Its innovative technology offers a potential competitive advantage. The company's long-term success hinges on securing partnerships, achieving regulatory approvals, and effectively scaling production. Investors should carefully consider the risks associated with development-stage companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
- Analyst Reports
- Third-party Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. This analysis is based on publicly available information and may not reflect all relevant factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuroone Medical Technologies Corp
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 2017-09-18 | President, CEO & Director Mr. David A. Rosa M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17 | Website https://nmtc1.com |
Full time employees 17 | Website https://nmtc1.com | ||
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, radio frequency and brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company also focuses on applications of its technology associated with artificial intelligence. It has partnership with RBC Medical Innovations to develop a radio frequency ablation generator. NeuroOne Medical Technologies Corporation is based in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.